LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · IEX Real-Time Price · USD
2.95
-0.06 (-1.99%)
Jun 30, 2022 11:35 AM EDT - Market closed
Income Statement (Annual)
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue
|
5 | 3.5 | 0 |
| Revenue Growth (YoY)
|
42.86% | - | - |
| Gross Profit
|
5 | 3.5 | 0 |
| Selling, General & Admin
|
12.16 | 2.72 | 1.24 |
| Research & Development
|
37.19 | 15.7 | 8.35 |
| Operating Expenses
|
49.35 | 18.42 | 9.58 |
| Operating Income
|
-44.35 | -14.92 | -9.58 |
| Interest Expense / Income
|
0.63 | 0.34 | 0.09 |
| Other Expense / Income
|
0.21 | 0.2 | 0.02 |
| Pretax Income
|
-45.19 | -15.46 | -9.69 |
| Income Tax
|
0.16 | 0.04 | 0 |
| Net Income
|
-45.35 | -15.51 | -9.69 |
| Net Income Common
|
-45.35 | -15.51 | -9.69 |
| Shares Outstanding (Basic)
|
20 | 0 | 0 |
| Shares Outstanding (Diluted)
|
20 | 0 | 0 |
| Shares Change
|
4850.36% | -10.81% | - |
| EPS (Basic)
|
-2.30 | -38.85 | -21.65 |
| EPS (Diluted)
|
-2.30 | -38.85 | -21.65 |
| Free Cash Flow Per Share
|
-1.49 | -24.58 | -20.95 |
| Gross Margin
|
100.00% | 100.00% | - |
| Operating Margin
|
-887.06% | -426.29% | - |
| Profit Margin
|
-906.94% | -443.03% | - |
| Free Cash Flow Margin
|
-588.22% | -280.26% | - |
| Effective Tax Rate
|
-0.35% | -0.28% | 0.00% |
| EBITDA
|
-44.01 | -14.66 | -9.34 |
| EBITDA Margin
|
-880.14% | -418.77% | - |
| Depreciation & Amortization
|
0.56 | 0.46 | 0.26 |
| EBIT
|
-44.57 | -15.12 | -9.6 |
| EBIT Margin
|
-891.30% | -432.03% | - |
Source: Financials are provided by
Nasdaq Data Link
and sourced from audited reports submitted to the
Securities and Exchange Commission
(SEC).